



# Resistance of Common Circulating Enteric Bacterial Pathogens to Prescribed Antibiotics Among Under Five Years in Selected Public Hospitals in Kenya

\*Sang W<sup>1</sup>, Too R<sup>1</sup>, Githii S<sup>2</sup>, Matey E<sup>1</sup>, Kiptoo M<sup>3</sup>, Wanzala P<sup>5</sup>, Kariuki J<sup>5</sup>, Githui W<sup>4</sup>

1. Kenya Medical Research Institute(KEMRI), Center for Microbiology Research,
2. Ministry of Health, Public Health Laboratory Services.
3. South Eastern Kenya University.
4. KEMRI, Centre for Respiratory Diseases Research
5. KEMRI, Center for Public Health Research

\*Corresponding Author: Sang W. Email: [willie.sang@usamru-k.org](mailto:willie.sang@usamru-k.org)

## Summary

### INTRODUCTION

Limited data on antimicrobial resistance (AMR) in *enteric* pathogens is available in Kenya yet diarrhea remains the main cause of morbidity and mortality among rural Kenyan children.

There was need to established antimicrobial susceptibility patterns of *enteric* bacterial pathogens to commonly prescribed antibiotics among children aged <5 years in selected cross-border Kenyan public hospitals between 2013 and 2016.

### METHODOLOGY

This was a hospital based cross-sectional study. Single stool samples were collected from 1644 outpatients presenting with diarrhea at Busia, Kitale, Malindi, Wajir, and Machakos public-hospitals from June 2013 to June 2016 and shipped to Kenya Medical Research Institute (KEMRI). Pathogenic *E. coli*, *Shigella* and *Salmonella sp.* were isolated using standard microbiological methods. *Multiplex Polymerase Chain Reaction (PCR)* was used to characterize *E. coli* isolates. Antimicrobial susceptibility testing was done using Kirby Bauer disc diffusion method.

### RESULTS

Out of the 1644 enrolled participants, bacterial pathogens identified were; Pathogenic *E. coli* in 232(14.1%), *Shigella* in 99 (5.4%) and *Salmonella* in 49(3.0%). High antimicrobial resistance (AMR) levels were observed. Highest AMR were observed for *Sulfamethoxazole* (93%) and Ampicillin (88%) for *E. coli* isolates, *Sulfamethoxazole* (89%) and Ampicillin (88%) for *Shigella* isolates, *Sulfamethoxazole* (73%) and Ampicillin (86%) for *Salmonella* isolates.

Emerging resistance at 15%(CI:10-19), 29%(CI:23-35), 14%(CI:9-18) for *E. coli*, 26%(CI:18-35), 55%(CI:45-64), 30%(CI:21-39) for *Shigella* and 31%(CI:18-44), 57%(CI:43-71) 29%(CI:16-41) for *Salmonella* were observed to Ciprofloxacin, Nalidixic acid and Gentamycin respectively.

### CONCLUSION

Pathogenic *E. coli* were the most prevalent *enteric* bacterial pathogens. Highest AMR were observed to *sulfamethoxazole* and ampicillin then emerging resistance to 3rd line antibiotics is of a major concern.

[*Afr. J. Health Sci.* 2019 32(4) : 35 - 42]



## Introduction

Diarrhea is a significant health problem worldwide, especially in the developing world where adequate sanitation facilities are lacking [1].

Globally diarrhoeal diseases account for almost a fifth of all deaths in children below 5 years, with an annual estimate of 2.2 million deaths [2].

The cause of diarrhea includes an array of viruses, parasites and bacteria [3]. The widespread use of antimicrobial agents in medical practice and animal husbandry has led to serious problems of antimicrobial resistance world over [4].

Increasing antimicrobial resistance of *enteric* commensals and *pathogens* has been a major topic both in developed and developing nations for quite a while [1]. The emergence and spread of antibiotic resistance in *enteric pathogens* pose a serious problem in Kenya. This has heightened sense of awareness and interest in bacterial diarrheal illnesses [5, 6].

There is a concern on lack of effective treatment for drug resistant organisms. This concern has been brought about by the recent increase in enteric disease outbreaks in Eastern Africa region.

Among the *enteric pathogens*, major drug resistant *Shigellae sp.*, *Salmonella typhi* strains and *Vibrio cholera spp.* have been reported in Kenya [7].

As a result, there is need to determine prevalence of these *pathogens* and their antimicrobial resistance profiles along the cross-border points of countries in the Eastern Africa region: Kenya, Uganda, and Tanzania.

This study aimed at determining the prevalence of common circulating *enteric* bacterial *pathogens* and their antimicrobial susceptibility patterns in select cross-border public hospitals in Kenya.

## Methodology

### Study Design

This was a hospital based cross-sectional study of all children aged five years and below who sought treatment for diarrheal illness from five (5) selected

cross-border county hospitals in Kenya. These were; Busia, Kitale, Wajir, Malindi and Machakos who were willing to participate in the study.

### Stool Sample Collection

The study was granted approval by the Scientific Ethics and Review Unit (SERU) at KEMRI. After obtaining consent, stool samples were collected between June 2013 and June 2016 from 1644 outpatient children presenting with diarrhea and were not on antibiotics in the last 72 hours.

Sample collection was done in sterile plastic containers. The specimens were transferred into Cary-Blair transport media (MML Diagnostics Inc. Troutdale, Oregon), labeled only with a unique study number, then packaged appropriately (Triple Packaging System) and transported to the Kenya Medical Research Institute (KEMRI), Nairobi Center for Microbiology Research (CMR) laboratories where they were processed.

## Sample Processing

### Bacterial Identification

All stool samples were plated onto MacConkey agar, Xylose-Lysine-Deoxycholate agar (XLD) and Sorbitol-MacConkey agar, (Oxoid Hampshire, England). The plates were incubated aerobically at 37°C for 18 to 24 hours.

Thereafter, one to two suspect colonies each of *Shigella* and *Salmonella* and five to ten colonies with typical *E. coli morphology* were selected and characterized on the basis of their biochemical reactions [8].

### Multiplex PCR

A multiplex PCR assay allowed the detection of eleven virulence markers in Pathogenic *E. coli*. Amplification parameters and primers for amplifying segments of genes of the *Shiga toxins* (*stx1*, *stx2*, and *eaeA*), *Cytotoxin necrotising* factors (*CNF1* and *CNF2*), attaching and effacing mechanisms (*eaeA*), *enteroaggregative* (EAEC), *enteroinvasive* mechanism (EIEC), and *enterotoxigenic* (ETEC) detection for heat-labile (LT) and heat stable (ST1 and ST2) toxins were used as described previously [9].



## Antimicrobial Susceptibility Testing

Antimicrobial susceptibility tests were conducted using *Kirby Bauer disc diffusion method* [10].

The following were commonly used antimicrobial agents (Basingstoke Hampshire, England). They were tested on all the isolates as per CLS guidelines 2016 using *E. coli* reference strain ATCC 25923 as a control. in hospitals:

*Ampicillin,*  
*Chloramphenicol,*  
*Ciprofloxacin,*  
*Tetracycline,*  
*Nalidixic acid,*  
*Furazolidine,*  
*Gentamycin,*  
*Cefotaxime,*  
*Sulfamethoxazole*

## Results

A total of 1644 participants were enrolled from five Kenyan hospitals serving cross-border counties as follows:

Busia	n =	291
Kitale	n =	492
Machakos	n =	70
Malindi	n =	387
Wajir	n =	404

Among the enrolled participants, *etiologies* of diarrheal were identified in 25.2% (n=415) cases as follows:

<i>Pathogenic E. coli</i>	14.1%	n =	232
<i>Shigella</i>	5.4%	n =	99
<i>Salmonella</i>	3.0%	n =	49

Distribution of *E. coli* pathotypes was:

Busia	16.5%
Kitale	10%,
Machakos	4.3%,
Malindi	15%
Wajir	18.3%

while distribution of *Shigella* was:

7.6%, 8.9%, 5.7%, 5.2%, and 2.2%

and that of *salmonella* was:

1.4%, 3%, 0%, 4.9% and 2.7%

in the five hospitals respectively (**Figure 1**).

Antimicrobial susceptibility testing was conducted on:

48, 49, 3, 58, and 74 *E. coli* isolates,  
22, 44, 4, 20, and 9 *Shigella* isolates  
4, 15, 19, 0 and 11 *salmonella* isolates

from Busia, Kitale, Machakos, Malindi and Wajir county cross-border hospitals respectively.

All the three *etiologies* of diarrhoeal showed resistance to the commonly prescribed antibiotics in Kenya though at varied levels.

Among the *E. coli* isolates, overall highest levels of resistance were observed in:

*Sulfamethoxazole* at 93% (95% CI: 90-96)  
*Ampicillin* at 88% (95% CI: 83-92)

respectively (**Table 1**).

Among *Shigella* isolates the highest levels of resistance were also observed in:

*Sulfamethoxazole* at 89% (95% CI: 69-100) and  
*ampicillin* at 88% (95% CI: 81-94)

respectively (**Table 1**)

while the highest resistance levels among the *Salmonella* isolates were in:

*ampicillin* at 86% (95% CI: 76-96),  
*tetracycline* and *sulfamethoxazole* both at 73%  
(95% CI: 61-86) (**Table 1**).

Disturbingly, emerging resistance to Nalidixic acid, Ciprofloxacin and Gentamycin was also observed among the three agents of diarrheal isolated and also at each of the cross border hospital.

Emerging resistance was observed as follows:

*E. coli*, at:

29%; (CI:23-35), 15%; (CI:10-19),  
14%; ( CI:9-18)

*Shigella* at:

55%;(CI:45-64), 26%; (CI:18-35),  
30%;(CI:21-39)

*Salmonella* spp.

57%;(CI:43-71), 31%;(CI:18-44),  
29%;(CI:16-41)

(**Table 1**).



**Table 1: Resistance Profiles Of Enteric Bacterial Pathogens To Commonly Prescribed Antibiotics In The Selected County Hospitals In Kenya**


Bacterial Isolates from Sites	Amp	Chl	Cip	Te	Nal	Fur	Gen	Ctx	Stx
	% (95%CI)	% (95%CI)	% (95%CI)	% (95%CI)	% (95%CI)	% (95%CI)	% (95%CI)	% (95%CI)	% (95%CI)
<b>E.coli</b>									
Busia (48)	92(84-100)	25(13-37)	10(2-18)	67(54-80)	25(13-37)	21(9-33)	10(2-18)	8(0-16)	98(94-100)
Kitale (49)	92(84-100)	33(20-46)	6(0-13)	78(66-90)	31(18-44)	18(7-29)	12(3-21)	20(9-31)	94(87-100)
Machakos(3)*	100(n/a)	0(n/a)	33(0-86)	67(14-100)	33(0-86)	0(n/a)	0(n/a)	67(14-100)	100(n/a)
Malindi (58)	90(82-98)	31(19-43)	12(4-20)	79(69-89)	29(17-41)	9(2-16)	7(0-14)	10(2-18)	93(86-100)
Wajir (74)	80(71-89)	16(8-24)	24(14-34)	69(58-80)	30(20-40)	11(4-18)	23(13-33)	28(18-38)	89(82-96)
Total(232)	<b>88(83-92)</b>	<b>25(19-31)</b>	<b>15(10-19)</b>	<b>73(67-79)</b>	<b>29(23-35)</b>	<b>14(9-18)</b>	<b>14(9-18)</b>	<b>19(18-24)</b>	<b>93(90-96)</b>
<b>Shigella</b>									
Busia(22)	100(n/a)	27(75-33)	18(2-34)	73(54-92)	59(38-80)	18(2-3)	27(8-46)	18(2-34)	91(79-100)
Kitale(44)	82(71-93)	55(40-70)	25(12-38)	80(68-92)	50(35-65)	25(12-38)	34(20-48)	18(7-29)	84(73-95)
Machakos(4) *	75(33-100)	50(1-99)	50(1-99)	75(33-100)	75(33-100)	50(1-99)	75(33-100)	50(1-99)	100(n/a)
Malindi(20)	90(77-100)	35(14-56)	20(2-38)	85(69-100)	40(19-61)	15(0-31)	20(2-38)	10(0-23)	95(85-100)
Wajir(9)	89(69-100)	33(2-64)	44(12-76)	78(51-100)	89(69-100)	33(2-64)	11(0-31)	44(12-76)	89(69-100)
Total(99)	<b>88(81-94)</b>	<b>42(33-52)</b>	<b>26(18-35)</b>	<b>77(68-85)</b>	<b>55(45-64)</b>	<b>23(15-32)</b>	<b>30(21-39)</b>	<b>21(13-29)</b>	<b>89(83-95)</b>
<b>Salmonella</b>									
Busia(4) *	100 (n/a)	75(33-100)	75(33-100)	100(n/a)	100(n/a)	50(1-99)	75(33-100)	50(1-99)	75(33-100)
Kitale(15)	73(51-95)	13(0-30)	13(0-30)	53(28-78)	27(5-49)	13(0-30)	13(0-30)	27(5-49)	60(35-85)
Malindi(19)	95(85-100)	47(25-69)	26(6-46)	79(61-97)	68(47-89)	32(11-53)	26(6-46)	21(3-39)	84(68-100)
Wajir(11)	82(59-100)	64(36-92)	45(16-74)	82(59-100)	64(36-92)	45(16-74)	36(8-64)	55(26-84)	73(47-99)
Total(49)	<b>86(76-96)</b>	<b>43(29-57)</b>	<b>31(18-44)</b>	<b>73(61-86)</b>	<b>57(43-71)</b>	<b>31(18-44)</b>	<b>29(16-41)</b>	<b>33(20-46)</b>	<b>73(61-86)</b>

\* Sample size inadequate to interpret resistance

Ampicillin (**Amp**), Chloramphenicol (**Chl**), Ciprofloxacin(**Cip**), Tetracycline(**Te**), Nalidixic acid(**Nal**), Furazolidine(**Fur**), Gentamycin(**Gen**), Cefotaxime (**Ctx**), sulfamethoxazole(**Stx**).



**Figure 1:** Distribution In Percentage(%) Of Common Circulating Enteric Bacterial Pathogens In Selected Kenyan Cross- Border Hospitals



## Discussion

Antimicrobial resistance (AMR) is a very critical healthcare, social and economic problem worldwide [11].

In Africa, it seems that same levels of antibiotic drug resistance are found in all regions and settings yet these regions are widely different in terms of Socio - Economic development. Based on published reports in Kenya antibiotic resistance has increased dramatically in the last 20 years [12].

Despite advances in diagnostic technology in some Hospitals in Kenya, many patients receive empiric treatment without evidence based laboratory identification of the causative agents.

Studies done in Kenya among the Maasai people fifteen years ago showed a high infection rate of *Pathogenic E. coli* especially in children with diarrhea who were under five years of age. Isolates from these children showed moderate resistance to antibiotics that were used than in treatment of diarrhea where it was necessary [13].





Moreover, the few recently reported studies about antimicrobial resistance among *diarrheogenic E. coli* and *Shigella* strains in children in Kenya show a high prevalence rate of resistance to commonly prescribed antibiotics for diarrheal illness [5, 14].

In this study, the susceptibilities of 232 diarrheogenic *E. coli*, 99 *Shigella*, 49 *Salmonella* isolates were tested for different antibiotics that are frequently prescribed at the study hospitals. In our study, the results showed that CIP, NAL, FUR, GEN and CTX had moderate activity amongst *Shigella* isolates.

However, previous studies in Kenya, especially in Malindi and Narok showed no resistant to these drugs [13]. In this case our results indicate an emerging resistance to *fluoroquinolone* (CIP), *quinolone* (NAL) and 3rd generation *cephalosporin* (CTX).

Therefore, it is of great concern while these antibiotics are used as the last option to treat infections, including traveler's diarrheal. The study showed a higher prevalence of resistance to STX, AMP, and TE in diarrheogenic *E. coli* compared to other studies elsewhere [14, 16].

Our study showed *pathogenic E. coli* as the most prevalent with high rates of resistance to AMP, STX and TE and moderate resistance was also noted to CHL, NAL and CTX, which are the commonly used drugs for treatment of diarrhea. Similar rates of resistance have been reported, [17, 18, 19].

On the contrary, a study by Vila et al. in a neighboring country, Tanzania, displayed high susceptibility of pathogenic *E. coli* to both NAL and CIP [20].

*Shigella spp* are becoming increasingly resistant to most antibiotics commonly used in the treatment of diarrhea [21, 22]. In the present study, the prevalence of resistance to STX and AMP were similar to those of other studies in developing countries [23, 24, 25].

In contrast, the study of Replogle et al. in United States showed lower prevalence of resistance of *Shigella*, with 59% resistant to STX and 63% resistant to AMP [26]

The lower resistance rates to these two antibiotics have also been reported by European

Union in Slovenia's summary report on antimicrobial resistance [27].

Many studies have reported multi-resistance in *Shigella* especially to STX and AMP, which are commonly used to treat *Shigellosis* [28, 29].

In our study, *Shigella* strains were resistant to:

STX at 89%,  
AMP at 88% and  
TE at 77%. Except for  
CHL and  
NAL

that showed moderate activity with *Shigella*, other antibiotics were showing decreased activity against this *pathogen*.

In this study the percentages of *Salmonella* resistance were:

AMP 86%, 73%  
TE, 43%  
CHL, and  
STX 73%

which were quite variable in contrast, with previous studies in Kenya that showed the lowest resistance rates to:

AMP at 53%,  
TET at 59%,  
CHL at 36%, and  
STX at 53% (5,30).

However, the lowest rates from Sri Lanka indicate a percentages ranging from 3% (resistance to CHL) to 10% (resistance to STX) [28].

## Conclusion

In conclusion, the progressive increase in antibiotic resistance among enteric pathogens, particularly in developing countries, is becoming a sensitive concern especially in selecting the appropriate treatment for an effective, inexpensive antimicrobial agent that can be used safely for treatment of children with diarrhea.

The immediate concern is knowledge of the resistance patterns of *enteric pathogens* to commonly prescribed antibiotics in Kenya.

## Acknowledgements

We thank the Ministry of Health officials especially the Medical Superintendents from Busia, Kitale, Malindi, Wajir and Machakos referral hospitals



Their Laboratory staff for the technical support in the preparation of research materials for the East African Public Health Laboratories Networking Project (EAPHLNP).

The East, Central and Southern Africa Health Community (ECSA-HC) - for coordination of the project.

The Director KEMRI and staff for facilitating the smooth running of the project

Finally The World Bank through the Ministry of Health- Kenya, for the financial support.

## Funding

The Study was funded by the World Bank through the Ministry of Health- Kenya.

Transparency declarations: None to declare.

## References

1. **Okeke IN, Lamikanra A, Steinrück H, et al.** Characterization of *Escherichia coli* strains from cases of childhood diarrhea in provincial southwestern Nigeria. *J. Clin Microbiol* 2000; 38: 7-12.
2. **Black RE, Morris SS, Bryce J.** Where and why are 10 million children dying every year? *Lancet* 2003; **361**: 2226-2234.
3. **Guerrant RL, Hughes JM, Lima NL, et al.** Diarrhea in developed and developing countries: magnitude, special settings, and etiologies. *Rev Infect Dis* 1990; 12 Suppl 1: S41-50.
4. **Economou V and Gousia P.** Agriculture and food animals as a source of antimicrobial-resistant bacteria. Published online 2015 Apr 1. doi: 10.2147/IDR.S55778
5. **Sang WK, Oundo V, Schnabel D.** Prevalence and antibiotic resistance of bacterial pathogens isolated from childhood diarrhea in four provinces of Kenya. *J Infect Dev Ctries* 2012; 6(7):572-578.
6. **Kariuki S, Revathi G, Corkill J et al.** *Escherichia coli* from community-acquired urinary tract infections resistant to *fluoroquinolones* and extended-spectrum *beta-lactams*. *J Infect Dev Ctries* 2007; 1: 257-262.
7. **Iijima Y, Oundo JO, Taga K et al.** Simultaneous outbreak due to *Vibrio cholerae* and *Shigella* dysenteriae in Kenya. *Lancet*. 1995; 345(8941):69-70.
8. **Quinn PJ, Carter ME, Markey B.** Clinical veterinary microbiology, *Mosby-Year Book, London England* 1994; pp: 209-236.
9. **Pass MA, Odedra R., Batt RM.** Multiplex PCRs for Identification of *Escherichia coli* virulence genes. *J Clin Microbiol* 2000; 38: 2001-2004.
10. **Bauer AW, Kirby WM, Sherris JC et al.** Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 1996; 45: 493-496.
11. **World Health organization.** The evolving threat of antimicrobial resistance: options for action. Geneva Switzerland WHO 2012 [www.who.int/entity/antimicrobial-resistance/publications/general-documents/en](http://www.who.int/entity/antimicrobial-resistance/publications/general-documents/en).
12. **Sang WK, Oundo JO, Mwituria JM et al.** Multidrug-Resistant Entero-aggregative *Escherichia coli* Associated with Persistent Diarrhea in Kenyan children. *Emerging Infectious Diseases*. 1997; 3 (3).
13. **Sang WK, Kariuki SM, Schnabel D et al.** Antibiotic susceptibility of *Enteric pathogens* from the Maasai community, Narok and Kajiado Districts, Kenya. *Africa Journal of Health Science*. 2011; 19:74-79.
14. **Bii CC, Taguchi H, Ouko TT et al.** Detection of virulence-related genes by multiplex PCR in multidrug-resistant *diarrheagenic Escherichia coli* isolates from Kenya and Japan. *Epidemiol Infect* 2005; 133: 627-633.
15. **George DF, Gbedema SY, Agyare C et al.** Antibiotic Resistance Patterns of *Escherichia coli* Isolates from Hospitals in Kumasi, Ghana. *ISRN Microbiology*. 2012; 5:10.5402.
16. **Yismaw G, Abay S, Asrat D et al.** Bacteriological profile and resistant pattern of clinical isolates from pediatric patients, Gondar University



- Teaching Hospital, Gondar, Northwest Ethiopia. *Ethiopian Medical Journal*. 2010; 48(4):293-300.
17. **Nguyen T, Van Le P, Huy Le C et al.** Antibiotic Resistance in Diarrheagenic *Escherichia coli* and *Shigella* Strains Isolated from Children in Hanoi, Vietnam. *Antimicrob Agents Chemother*. 2005; 49(2) : 816–819.
  18. **Heidary M, Momtaz H and Madani M.** Characterization of Diarrheagenic Antimicrobial Resistant *Escherichia coli* Isolated from Pediatric Patients in Tehran, Iran. *Iran Red Crescent Med J*. 2014 ; 16(4) : e12329.
  19. **Alikhani MY, Hashemi SH, Aslani MM et al.** Prevalence and antibiotic resistance patterns of diarrheagenic *Escherichia coli* isolated from adolescents and adults in Hamedan, Western Iran. *J. Microbiol*. 2013 ; 5(1): 42 – 47.
  20. **Vila J, Vargas M, Casals C et al.** Antimicrobial Resistance of Diarrheagenic *Escherichia coli* Isolated from Children under the Age of 5 Years from Ifakara, Tanzania. *Antimicrob. Agents Chemother*. 1999 ; 43(12): 3022 - 3024.
  21. **Geeta S, Acharya J, Adhikari S et al.** Shigellosis in Nepal: 13 years review of nationwide surveillance. *Journal of Health, Population and Nutrition*. 2016 ; 35 : 36.
  22. **Sang WK, Too R, Githii S et al.** Emerging antimicrobial resistance patterns of enteric pathogens isolated from children under 5 years of age in five EAPHLNP satellite sites in Kenya. *African Journal of Health Sciences*. 2014 ; 27 : 4
  23. **Randrianirina F, Ratsima EH, Ramparany L et al.** Antimicrobial resistance of bacterial enteropathogens isolated from stools in Madagascar. *BMC Infectious Diseases*. 2014 14:104.
  24. **Amaya E, Reyes D, Vilchez S et al.** Antibiotic resistance patterns of intestinal *Escherichia coli* isolates from Nicaraguan children. *Journal of Medical Microbiology*. 2011; 60 : 216 - 222.
  25. **Chiyangi H, Muma J, Malama S et al.** Identification and antimicrobial resistance patterns of bacterial enteropathogens from children aged 0–59 months at the University Teaching Hospital, Lusaka, Zambia: a prospective cross sectional study. *BMC Infect Dis*. 2017; 17: 117.
  26. **Replogle M L, Fleming D. W, Cieslak PR.** Emergence of antimicrobial-resistant shigellosis in Oregon. *Clin. Infect. Dis*.2000; 30 :5 15 - 519.
  27. **The European Union** summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2014 European Food Safety Authority European Centre for Disease Prevention and Control page 42 and 43. *EFSA Journal*. 2016 ; 14(2) : 4380.
  28. **Poramathikul K, Bodhidatta L, Chiek S et al.** Multidrug –resistant *Shigella* infections in patients with diarrhea in Cambodia 2014-2015. *Emerging infectious diseases* 2016 ; 22 : 9.
  29. **Ud-Din AI, Wahid S, Latif HA et al.** Changing Trends in the Prevalence of *Shigella* Species: Emergence of Multi-Drug Resistant *Shigella Sonnei* Biotype g in Bangladesh. *Journal pone*. 2013; 10:1371.
  30. **Brooks J. T, Ochieng J. B, Kumar L et al.** Surveillance for bacterial diarrhea and antimicrobial resistance in rural Western Kenya. *Clin. Infect Dis*. 2006; 43: 393-401.